ReviewNature reviews. Gastroenterology & hepatology2015
Nanomedicines in gastroenterology and hepatology.
Review in Nature reviews. Gastroenterology & hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Multi-modal therapeutic approaches to inflammatory bowel disease: plant-derived compounds, nanoparticle drug delivery systems, and gene-based interventions.Molecular biology reports · 2026Review
- Synergistic Effect of Nanoparticles with Probiotics on Gastrointestinal Regenerative Medicine.Probiotics and antimicrobial proteins · 2026Review
- Current Therapeutic Strategies, Recent Advances and the Emerging Potential of Natural Products in Hepatocellular Carcinoma.Scientifica · 2026Review
- Fluidic microgel assemblies with enhanced oral delivery of biologics alleviate colonic inflammation in murine and canine models.Science advances · 2025Article
- Mapping research hotspots and trends in hepatocellular carcinoma nanomedicine: a bibliometric analysis.Discover oncology · 2025Article
- Biogenic Zinc Oxide Nanoparticles as a Promising Antibacterial Agent: Synthesis and Characterization.International journal of molecular sciences · 2024Review
- Unleashing the promise of emerging nanomaterials as a sustainable platform to mitigate antimicrobial resistance.RSC advances · 2024Review
- Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota regulation.Journal of nanobiotechnology · 2024Article
- Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.Pharmaceutics · 2023Review
- Nanotechnology for research and treatment of the intestine.Journal of nanobiotechnology · 2022Review
- Plant Extracts Mediated Metal-Based Nanoparticles: Synthesis and Biological Applications.Biomolecules · 2022Review
- Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting.Pharmaceutics · 2022Article
- Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease.Biomedicines · 2021Review
- Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.Nanoscale horizons · 2021Article
- Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring.Pharmaceutics · 2021Review
- Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure.Nano-micro letters · 2020Review
- Bioresponsive drug delivery systems for the treatment of inflammatory diseases.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Antioxidant Nanotherapies for the Treatment of Inflammatory Diseases.Frontiers in bioengineering and biotechnology · 2020Review
- Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy.Asian journal of pharmaceutical sciences · 2019Review
- A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory Bowel Disease by Regulating Proinflammatory Microenvironment and Gut Microbiota.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoscale systems are currently under investigation for multiple different diagnostic and therapeutic applications. These systems can be used to identify pathologically changed tissues or to selectively deliver drugs to these sites; both applications have an extremely high potential to ameliorate therapeutic outcomes for patients. Tissues as well as single cells can be targeted because of the small size of these systems, which enables enhanced diagnosis and increased specificity of therapy. Drug loads can be delivered directly to the site of action, which can result in a reduction in incidence and severity of adverse systemic effects. Several nano-based platform technologies are currently under investigation for use in therapeutic approaches, mainly for anti-inflammatory and anti-cancer therapies. Although many nanoscale systems show promising therapeutic outcomes in preclinical studies, only a limited number are ready for clinical use. This Review will discuss the diverse nanomaterials currently available and the first specific uses for select gastroenterological and hepatological pathologies. The discussion of diagnostic and therapeutic applications will consider realities of market introduction of these sometimes very complex systems in light of remaining regulatory challenges and hurdles for industrial production.
Indexed as
Identifiers
25752711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.